tradmap

BBNX Earnings Beta Bionics, Inc.

Reported EPS, revenue and net income by fiscal period (SEC EDGAR) — quarterly and annual. Full financials → Chart & overview → Latest filing

Annual results

Diluted EPS (annual)
-$9 -$4 $0 2023 2024 2025
EPS
Revenue (annual)
$0 $50M $100M 2023 2024 2025
Revenue
Net income (annual)
-$73M -$37M $0 2023 2024 2025
Net income

Quarterly results

Diluted EPS (quarterly)
-$3 -$1 $0 Q1 '24 Q3 '24 Q1 '25 Q3 '25 Q1 '26 Q3 '26
EPS
Revenue (quarterly)
$0 $18M $36M Q1 '24 Q3 '24 Q1 '25 Q3 '25 Q1 '26 Q3 '26
Revenue
Net income (quarterly)
-$29M -$14M $0 Q1 '24 Q3 '24 Q1 '25 Q3 '25 Q1 '26 Q3 '26
Net income

Reported EPS history

1–14 of 14
Q3 20262026-09-30-0.522026-10-2710-Q
Q2 20262026-06-30-0.532026-07-2910-Q
Q1 20262026-03-31-0.492026-04-2110-Q
Q4 2025 (derived)2025-12-31-0.162026-02-2410-K
FY 20252025-12-31-1.812026-02-2410-K
Q3 20252025-09-30-0.332025-10-2810-Q
Q2 20252025-06-30-0.392025-07-2910-Q
Q1 20252025-03-31-0.932025-05-0610-Q
Q4 2024 (derived)2024-12-31-2.702025-03-2510-K
FY 20242024-12-31-8.602025-03-2510-K
Q3 20242024-09-30-1.46——
Q2 20242024-06-30-2.37——
Q1 20242024-03-31-2.07——
FY 20232023-12-31-8.31——

Source: SEC EDGAR / XBRL (reported actuals; no consensus estimates). Some issuers (e.g. mortgage REITs, banks) don't report a conventional revenue line, so those charts may be omitted. Q4 EPS marked "derived" is computed as the fiscal-year EPS minus Q1–Q3 (10-Ks report only the annual figure); EPS is not strictly additive across quarters, so it can differ by a cent or two from the issuer's own Q4. A period with no "Reported" date is known only from a later filing's prior-year comparative. Informational only — not financial advice.